EVGN Evogene Ltd.
Healthcare$0.71+1.29%ClosedMarket Cap: $6.1M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-2.72
P/S
3.34
EV/EBITDA
0.03
DCF Value
$-4.64
FCF Yield
-196.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
30.9%
Operating Margin
-757.2%
Net Margin
-639.4%
ROE
934.8%
ROA
-65.4%
ROIC
-104.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $3.9M | -6.3% | $-14.0M | $-7.8M | $— | — |
| Q4 null | $314.0K | -627.4% | $-5.2M | $-5.3M | $— | — |
| FY null | $3.9M | -6.3% | $-14.0M | $-8.5M | $— | — |
| Q3 null | $312.0K | 49.7% | $-2.7M | $3.9M | $— | — |
| Q2 null | $884.0K | 84.6% | $-3.1M | $-4.5M | $— | — |
| Q1 null | $2.4M | 34.0% | $-4.1M | $-2.6M | $— | — |
| Q4 null | $1.6M | 53.1% | $-4.6M | $427.0K | $— | — |
| FY null | $5.6M | 57.3% | $-18.8M | $-16.5M | $— | — |
| Q3 null | $1.7M | 40.1% | $-5.9M | $-7.6M | $— | — |
| Q2 null | $605.0K | 44.5% | $-4.6M | $-5.4M | $— | — |
| Q1 null | $4.2M | 76.6% | $-3.6M | $-3.9M | $— | — |
| Q4 2023 | $578.0K | -83.6% | $-7.6M | $-6.6M | $-1.30 | — |